What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2022-09-09 compared with 2022-06-10 · 170 added, 195 removed, 539 unchanged (40% of the section changed)

10 unchanged sentences

Operating lease right-of-use

LIABILITIES AND

LIABILITIES AND EQUITY

Current liabilities:

1 unchanged sentence

Accrued expenses

Operating lease liability

Total current liabilities

lease liability

current liabilities

Operating lease liability,

Total liabilities

Commitments and contingencies (Note 9)

Shareholders’ equity:

Preferred stock, par value $ 100 per share;

Preferred stock, par value

$ 100 per share;

19,860 shares authorized;

no shares issued or outstanding

Series A convertible

preferred stock, par value $ 100 per share;

Series A convertible preferred

stock, par value $ 100 per share;

140 shares authorized;

1 unchanged sentence

Preferred stock

Common stock, par value $ .01 per share;

Common stock, par value

$ .01 per share;

100,000,000 shares authorized;

30,154,708 and 30,050,894 shares issued and outstanding as of April 30, 2022 and October 31, 2021,

30,653,418 and 30,050,894 shares issued and outstanding as of July 31, 2022 and October

31, 2021, respectively

Additional paid-in capital

9 unchanged sentences

For the three months ended

For the six months ended

For the nine months ended

Operating costs and expenses:

Inventor royalties, contingent

legal fees, litigation and licensing expenses

Inventor royalties,

contingent legal fees, litigation and licensing expenses

Research and development

16 unchanged sentences

thousands, except share data)

THE THREE MONTHS ENDED APRIL 30, 2022

THE THREE MONTHS ENDED JULY 31, 2022

Shareholders’

Balance, January 31, 2022

Balance, April 30, 2022

$ ( 212,163 )

Stock option compensation to employees and

Stock options and warrants issued to consultants

Stock options issued to consultants

Common stock issued upon exercise of stock

Common stock issued to consultants

Common stock issued pursuant to employee stock

purchase plan

Balance, April 30, 2022

Balance, July 31, 2022

$ ( 214,909 )

THE THREE MONTHS ENDED APRIL 30, 2021

THE THREE MONTHS ENDED JULY 31, 2021

Shareholders’

Balance, January 31, 2021

Balance, April 30, 2021

$ ( 196,443 )

Stock option compensation to employees and

Stock options and warrants issued to consultants

Common stock issued upon exercise of stock

Common stock issued pursuant to employee stock

purchase plan

Common stock issued in a public offering, net

of offering expenses of $ 2,208

Common stock issued in at-the-market offering,

net of offering expenses of $ 156

Balance, April 30, 2021

Expired restricted stock award to employee

( 1,500,000 )

Stock options issued to consultants

Balance, July 31, 2021

$ ( 200,777 )

accompanying notes are an integral part of these condensed consolidated financial statements.

3 unchanged sentences

thousands, except share data)

THE SIX MONTHS ENDED APRIL 30, 2022

THE NINE MONTHS ENDED JULY 31, 2022

Shareholders’

4 unchanged sentences

Common stock issued upon exercise of stock

options and warrants

Common stock issued to consultants

1 unchanged sentence

purchase plan

Balance, April 30, 2022

Balance, July 31, 2022

$ ( 214,909 )

THE SIX MONTHS ENDED APRIL 30, 2021

Shareholders’

THE NINE MONTHS ENDED JULY 31, 2021

Balance, October 31, 2020

1 unchanged sentence

Stock option compensation to employees and

Expired restricted stock award to employee

( 1,500,000 )

Stock options and warrants issued to consultants

2 unchanged sentences

purchase plan

Common stock issued in a public offering, net

of offering expenses of $ 2,208

Common stock issued in a public offering,

offering expenses of $ 2,208

Common stock issued in at-the-market offering,

net of offering expenses of $ 341

Balance, April 30, 2021

Balance, July, 2021

$ ( 200,777 )

3 unchanged sentences

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

the six months ended April 30,

the nine months ended July 31,

Cash flows from operating activities:

23 unchanged sentences

from sale of equipment

cash provided by (used in) investing activities

cash used in investing activities

Cash flows from financing activities:

5 unchanged sentences

Expenses of the at-the-market

Proceeds from sale of common

stock pursuant to employee stock purchase plan

Proceeds from sale of

common stock pursuant to employee stock purchase plan

from exercise of stock options

3 unchanged sentences

at beginning of period

Cash and cash equivalents at end of period

Cash and cash equivalents

at end of period

accompanying notes are an integral part of these condensed consolidated financial statements.

2 unchanged sentences

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BUSINESS AND FUNDING

used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences,

4 unchanged sentences

T-cell therapy, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian

cancer, which is being developed at our subsidiary, Certainty Therapeutics, Inc.

cancer, which is being developed by our subsidiary, Certainty Therapeutics, Inc.

(“Certainty”), and (ii) the discovery and

21 unchanged sentences

Phase 1 clinical trial.

We began patient recruitment for the trial in March 2022, and that process is ongoing.

This study is a dose-escalation

trial with two arms based on injection method—intraperitoneal or intravenous—to determine the maximum tolerated dose in patients

with recurrent epithelial ovarian cancer and to assess persistence, expansion and efficacy of the modified T-cells.

The study is being

conducted at Moffitt and will consist of 24 to 48 patients who have received at least two prior lines of chemotherapy.

The study is estimated

to be completed in two to four years depending on multiple factors including when maximum tolerated dose is reached and the rate of patient

We began patient recruitment for the trial in March 2022, and in August 2022, we treated the first patient in

The treatment appears to have been well-tolerated by the patient, and we continue to monitor her condition.

The process of

recruiting additional patients is ongoing.

This study is a dose-escalation trial with two arms based on injection method—intraperitoneal

or intravenous—to determine the maximum tolerated dose in patients with recurrent epithelial ovarian cancer and to assess persistence,

expansion and efficacy of the modified T-cells.

The study is being conducted at Moffitt and will consist of 24 to 48 patients who have

received at least two prior lines of chemotherapy.

The study is estimated to be completed in two to four years depending on multiple

factors including when maximum tolerated dose is reached and the rate of patient recruitment.

April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”) to discover and ultimately develop anti-viral

100 unchanged sentences

and Management’s Plans

on currently available information as of June 10, 2022, we believe that our existing cash, cash equivalents, short-term investments

and expected cash flows will be sufficient to fund our activities for at least the next twelve months.

We have implemented a business

model that conserves funds by collaborating with third parties to develop our technologies.

However, our projections of future cash needs

and cash flows may differ from actual results.

If current cash on hand, cash equivalents, short-term investments and cash that may be

generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a

company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required

to obtain more working capital.

We may seek to obtain working capital during our fiscal year 2022 or thereafter through sales of our

equity securities or through bank credit facilities or public or private debt from various financial institutions where possible.

cannot be certain that additional funding will be available on acceptable terms, or at all.

If we do identify sources for additional

funding, the sale of additional equity securities or convertible debt will result in dilution to our stockholders.

We can give no assurance

that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that

other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed,

on favorable terms or at all.

If we fail to obtain additional working capital as and when needed, such failure could have a material

adverse impact on our business, results of operations and financial condition.

Furthermore, such lack of funds may inhibit our ability

to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly

harm the business and development of operations.

on currently available information as of September 9, 2022, we believe that our existing cash, cash equivalents, short-term

investments and expected cash flows will be sufficient to fund our activities for at least the next twelve months.

implemented a business model that conserves funds by collaborating with third parties to develop our technologies.

projections of future cash needs and cash flows may differ from actual results.

If current cash on hand, cash equivalents,

short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our

business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with

or complementary to our technologies, we may desire or be required to obtain more working capital.

We may seek to obtain working

capital during our fiscal year 2022 or thereafter through sales of our equity securities (including, but not limited to, sales

through an at-the-market offering program under a universal shelf registration statement) or through bank credit facilities or public or

private debt from various financial institutions where possible.

We cannot be certain that additional funding will be available on

acceptable terms, or at all.

If we do identify sources for additional funding, the sale of additional equity securities or

convertible debt will result in dilution to our stockholders.

We can give no assurance that we will generate sufficient cash flows

in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of

equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all.

to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results

of operations and financial condition.

Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures

or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and

development of operations.

of Presentation

accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting

principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form

10-Q and Rule 8-03 of Regulation S-X.

Accordingly, certain information and disclosures required by generally accepted accounting principles

in annual financial statements have been omitted or condensed.

These interim condensed consolidated financial statements should be read

in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K

for the year ended October 31, 2021.

The accompanying October 31, 2021 condensed consolidated balance sheet data was derived from the

audited financial statements but does not include all disclosures required by US GAAP.

The condensed consolidated financial statements

include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial

position as of April 30, 2022, and results of operations and cash flows for the interim periods represented.

The results of operations

for the three and six months ended April 30, 2022 are not necessarily indicative of the results to be expected for the entire year.

accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted

accounting principles in the United States of America (“US GAAP”) for interim financial information and with the

instructions to Form 10-Q and Rule 8-03 of Regulation S-X.

Accordingly, certain information and disclosures required by generally

accepted accounting principles in annual financial statements have been omitted or condensed.

These interim condensed consolidated

financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures

included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2021.

The accompanying October 31, 2021 condensed

consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by

The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion

of management, are necessary for a fair statement of our financial position as of July 31, 2022, and results of operations and cash

flows for the interim periods presented.

The results of operations for the three and nine months ended July 31, 2022 are not

necessarily indicative of the results to be expected for the entire year.

Noncontrolling

2 unchanged sentences

The following table sets

forth the changes in noncontrolling interest for the six months ended April 30, 2022 (in thousands):

forth the changes in noncontrolling interest for the nine months ended July 31, 2022 (in thousands):

SCHEDULE OF NONCONTROLLING INTEREST AS A COMPONENT OF EQUITY

2 unchanged sentences

to noncontrolling interest

Balance, April 30, 2022

Balance, July 31, 2022

revenue has been derived solely from technology licensing and the sale of patented technologies.

27 unchanged sentences

and Development Expenses

and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities

and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities, including expenses related to clinical trials,

and other direct costs associated with developing immuno-therapy drugs against cancer, developing anti-viral drug candidates for COVID-19,

1 unchanged sentence

in the period incurred.

BASED COMPENSATION

Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock

SHARE BASED COMPENSATION

Company maintains equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock

appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants.

3 unchanged sentences

(the vesting period of the stock option) which is one to four years .

We recorded stock-based compensation expense related to service-based

stock options granted to employees and directors of approximately $ 875,000 and $ 881,000 during the three months ended April 30, 2022

and 2021, respectively, and approximately $ 1,605,000 and $ 1,756,000 during the six months ended April 30, 2022 and 2021, respectively.

We recorded share-based compensation expense related to service-based

stock options granted to employees and directors of approximately $ 941,000 and $ 1,066,000 during the three months ended July 31, 2022

and 2021, respectively, and approximately $ 2,546,000 and $ 2,822,000 during the nine months ended July 31, 2022 and 2021, respectively.

stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company’s

6 unchanged sentences

We recorded market condition stock-based

compensation expense during the three months ended April 30, 2022 and 2021 of approximately $ 587,000 and $ 0 , respectively, and approximately

$ 1,993,000 and $ 0 during the six months ended April 30, 2022 and 2021, respectively.

compensation expense during the three months ended July 31, 2022 and 2021 of approximately $ 388,000 and $ 1,981,000 , respectively, and

approximately $ 2,381,000 and $ 1,981,000 during the nine months ended July 31, 2022 and 2021, respectively.

compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the

2 unchanged sentences

We recorded stock-based consulting expense related to stock options granted

to consultants of approximately $ 109,000 and $ 132,000 during the three months ended April 30, 2022 and 2021, respectively, and approximately

$ 218,000 and $ 186,000 during the six months ended April 30, 2022 and 2021, respectively.

the three months ended April 30, 2022, we had two stock option plans:

to consultants of approximately $ 109,000 and $ 139,000 during the three months ended July 31, 2022 and 2021, respectively, and approximately

$ 546,000 and $ 421,000 during the nine months ended July 31, 2022 and 2021, respectively.

the three months ended July 31, 2022, we had two stock option plans:

the Anixa Biosciences, Inc.

1 unchanged sentence

“2010 Share Plan”) and the Anixa Biosciences, Inc.

2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted

by our Board of Directors on July 14, 2010 and January 25, 2018, respectively.

The 2018 Share Plan was approved by our shareholders on

March 29, 2018.

2018 Share Incentive Plan (the “2018 Share Plan”), which

were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively.

The 2018 Share Plan was approved by our

shareholders on March 29, 2018.

Option Activity

the three months ended April 30, 2022 and 2021, we granted options to purchase 1,400,000

shares and 250,000

shares of common stock, respectively, and during

the six months ended April 30, 2022 and 2021, we granted options to purchase 1,430,000

shares and 1,380,000

shares of common stock, respectively, to employees

and consultants, with exercise prices ranging from $ 2.62

per share, pursuant to the 2018 Share Plan.

the three months ended April 30, 2022 and 2021, stock options to purchase 0

shares of common stock and 77,571

shares of common stock, net of 7,937

shares withheld on a cashless exercise, respectively,

were exercised with aggregate proceeds of $ 0

respectively.

During the six months ended April 30, 2022 and 2021, stock options to purchase 46,909

shares of common stock, net of 53,091

shares withheld on a cashless exercise and 107,451

shares of common stock, net of 7,937

shares withheld on a cashless exercise, respectively,

were exercised with aggregate proceeds of $ 0

respectively.

the three months ended July 31, 2022 and 2021, we granted options to purchase 0 shares and 120,000 shares of common stock, respectively,

and during the nine months ended July 31, 2022 and 2021, we granted options to purchase 1,430,000 shares and 1,500,000 shares of common

stock, respectively, to employees and consultants, with exercise prices ranging from $ 2.62 to $ 5.30 per share, pursuant to the 2018 Share

During the three months ended July 31, 2022, stock options to purchase 1,001,388 shares of common stock, net of 505,340 shares

withheld on a cashless exercise, were exercised with aggregate proceeds of $ 830,000 .

During the three months ended July 31, 2021, no

stock options were exercised.

During the nine months ended July 31, 2022 and 2021, stock options to purchase 1,101,388 shares of common

stock, net of 558,431 shares withheld on a cashless exercise, and 115,388 shares of common stock, net of 7,937 shares withheld on a cashless

exercise, respectively, were exercised with aggregate proceeds of $ 830,000 and $ 293,000 , respectively.

2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and

2 unchanged sentences

respect to the ability to grant future awards on July 14, 2020.

Information regarding the 2010 Share Plan for the six months ended April

Information regarding the 2010 Share Plan for the nine months ended July

31, 2022 is as follows:

5 unchanged sentences

Options outstanding at October 31, 2021

Options outstanding

and exercisable at

April 30, 2022

following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2022:

Options outstanding and exercisable at July

following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2022:

SCHEDULE OF OUTSTANDING AND EXERCISABLE

Exercise Prices

Outstanding and

Contractual Life

Exercise Price

2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards,

performance awards and stock units to employees, directors and consultants.

As of April 30, 2022, the 2018 Share Plan had 600,000 shares

available for future grants.

Information regarding the 2018 Share Plan for the six months ended April 30, 2022 is as follows:

SCHEDULE OF OPTION ACTIVITY

As of July 31, 2022, the 2018 Share Plan had 600,000

shares available for future grants.

regarding the 2018 Share Plan for the nine months ended July 31, 2022 is as follows:

OF OPTION ACTIVITY

Average Exercise

2 unchanged sentences

(in thousands)

Options outstanding at October 31, 2021

Options outstanding at April 30, 2022

Options exercisable at April 30, 2022

following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of April 30, 2022:

outstanding at October 31, 2021

outstanding at July 31, 2022

exercisable at July 31, 2022

following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2022:

SCHEDULE OF OUTSTANDING AND EXERCISABLE

Exercise Prices

Contractual Life

Exercise Price

Contractual Life

Exercise Price

addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved

1 unchanged sentence

Information regarding stock options that were granted outside of share

plans for the six months ended April 30, 2022 is as follows:

plans for the nine months ended July 31, 2022 is as follows:

SCHEDULE OF OPTION ACTIVITY

5 unchanged sentences

Options outstanding

and exercisable at

April 30, 2022

and exercisable at July 31, 2022

following table summarizes information about stock options outstanding and exercisable that were granted outside of share plans as of

April 30, 2022:

July 31, 2022:

SCHEDULE OF OUTSTANDING AND EXERCISABLE

Average Remaining Contractual Life

Exercise Price

stock awards granted to employees, directors and consultants that vest upon grant, we recognize expense at the date of grant based on

the grant date closing price of the underlying common stock.

We did not grant any stock awards that vested upon grant during the six

months ended April 30, 2022 or 2021.

Stock Purchase Plan

5 unchanged sentences

by our shareholders on September 27, 2018.

During the six months ended April 30, 2022 and 2021, employees purchased 2,389 and 1,634 shares,

During the nine months ended July 31, 2022 and 2021, employees purchased 2,389 and 1,634 shares,

respectively, with aggregate proceeds of approximately $ 7,000 and $ 3,000 , respectively.

1 unchanged sentence

over five months , to a consultant for investor relations services.

We recorded consulting expense of approximately $ 38,000 and $ 96,000 ,

respectively, during the three and six months ended April 30, 2021, based on the fair value of the warrant on the date of grant recognized

on a straight-line basis over the vesting period.

On November 16, 2021, the warrant was exercised on a cashless basis and 25,484 shares

were withheld as payment.

We recorded consulting expense of approximately $ 0 and $ 96,000 , respectively,

during the three and nine months ended July 31, 2021, based on the fair value of the warrant on the date of grant recognized on a straight-line

basis over the vesting period.

On November 16, 2021, the warrant was exercised on a cashless basis and 25,484 shares were withheld as

November 1, 2021 we issued a warrant, expiring on October 30, 2026 , to purchase 60,000 shares of common stock at $ 4.77 per share, vesting

over five months , to a consultant for investor relations services.

We recorded consulting expense of approximately $ 110,000 and $ 220,000 ,

respectively, during the three and six months ended April 30, 2022, based on the fair value of the warrant on the date of grant recognized

on a straight-line basis over the vesting period.

of April 30, 2022, we also had warrants outstanding to purchase 300,000 shares of common stock at $ 6.56 per share, issued during fiscal

We recorded consulting expense of approximately $ 0 and $ 220,000 , respectively,

during the three and nine months ended July 31, 2022, based on the fair value of the warrant on the date of grant recognized on a straight-line

basis over the vesting period.

The warrant terminated in May 2022 upon termination of the consulting agreement.

of July 31, 2022, we also had warrants outstanding to purchase 300,000 shares of common stock at $ 6.56 per share, issued during fiscal

year 2021 and expiring on March 22, 2026 .

VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

GAAP defines fair value and establishes a framework for measuring fair value.

14 unchanged sentences

assumptions a market participant would use in pricing the asset and liabilities.

following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of April 30, 2022:

following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of July 31, 2022:

SCHEDULE OF FAIR VALUE MEASUREMENTS

5 unchanged sentences

Short-term investments

treasury bills

Total financial assets

10 unchanged sentences

Cash balances are stated at carrying value which approximates fair value.

ACCRUED EXPENSES

expenses consist of the following as of:

OF ACCRUED EXPENSES

(in thousands)

Payroll and related expenses

1 unchanged sentence

Accrued other

LOSS PER SHARE OF COMMON STOCK

NET LOSS PER SHARE OF COMMON STOCK

net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares

3 unchanged sentences

is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive.

reason, excluded from the calculation of Diluted EPS for the six months ended April 30, 2022 and 2021, were stock options to purchase

reason, excluded from the calculation of Diluted EPS for the nine months ended July 31, 2022 and 2021, were stock options to purchase

11,094,104 and 10,303,626 shares, respectively, and warrants to purchase 300,000 and 860,000 shares, respectively.

OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321),

55 unchanged sentences

could be subject to limitations under Internal Revenue Code section 382.

We have no unrecognized income tax benefits as of April 30,

2022 and October 31, 2021 and we account for interest and penalties related to income tax matters, if any, in general and administrative

We have no unrecognized income tax benefits as of July 31, 2022

and October 31, 2021 and we account for interest and penalties related to income tax matters, if any, in general and administrative expenses.

lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California (our principal executive offices)

6 unchanged sentences

with a discount rate of 10 %.

Rent expense was approximately $ 17,000 and $ 16,000 , respectively, for the three months ended April 30, 2022

and 2021, and approximately $ 33,000 and $ 32,000 , respectively, for the six months ended April 30, 2022 and 2021.

Rent expense was approximately $ 17,000 and $ 16,000 , respectively, for the three months ended July 31, 2022

and 2021, and approximately $ 50,000 and $ 48,000 , respectively, for the nine months ended July 31, 2022 and 2021.

operating leases, the lease liability is initially measured at the present value of the unpaid lease payments.

The remaining 50 -month

lease term as of April 30, 2022 for the Company’s lease includes the noncancelable period of the lease and the additional two-year

lease term as of July 31, 2022 for the Company’s lease includes the noncancelable period of the lease and the additional two-year

option period that the Company expects to exercise.

All right-of-use assets are reviewed for impairment when indications of impairment

of April 30, 2022, the annual minimum future lease payments of our operating lease liabilities were as follows:

of July 31, 2022, the expected annual minimum future lease payments of our operating lease liabilities were as follows:

OF MINIMUM LEASE PAYMENTS

For Periods Ended October 31,

Ended October 31,

(in thousands)

Total future minimum lease

payments, undiscounted

2022 (remaining)

future minimum lease payments, undiscounted

Imputed interest

Present value of future

minimum lease payments

AND CONTINGENCES

value of future minimum lease payments

COMMITMENTS AND CONTINGENCES

than lawsuits related to the enforcement of our patent rights, we are not a party to any material pending legal proceedings, nor are

19 unchanged sentences

adverse impact on the Company’s business, results of operations and financial condition.

SEGMENT INFORMATION

follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”).

9 unchanged sentences

The following represents selected financial information for our segments for the three

and six months ended April 30, 2022 and 2021 and as of April 30, 2022 and October 31, 2021, in thousands:

and nine months ended July 31, 2022 and 2021 and as of July 31, 2022 and October 31, 2021, in thousands:

OF SEGMENT INFORMATION

the Three Months Ended April 30,

the Six Months

Ended April 30,

the Three Months

the nine Months

Ended July 31,

CAR-T Therapeutics

4 unchanged sentences

costs and expenses excluding non-cash share-based compensation

Operating costs and

expenses excluding non-cash share based compensation:

Operating costs and expenses

excluding non-cash share based compensation:

CAR-T Therapeutics

1 unchanged sentence

Anti-Viral Therapeutics

costs and expenses excluding non-cash share based compensation expense

Operating costs and

expenses excluding non-cash share based compensation

Total assets:

5 unchanged sentences

Company’s consolidated revenue of $ 513,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $ 385,000

for the six months ended April 30, 2021 were solely related to our encrypted audio/video conference calling technology, which is included

for the nine months ended July 31, 2021 were solely related to our encrypted audio/video conference calling technology, which is included

in our Other segment.

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements